Sam Brusco, Associate Editor03.07.22
Orthobiologics company Bone Biologics began a supply agreement with MTF Biologics, a nonprofit allograft tissue provider, for demineralized bone matrix (DBM).
Bone Biologics’ bone graft substitute rhNELL-1 for spinal fusion is in development and will be supplied by MTF for bone formation initiation and improvement. The agreement provides material for the company’s planned 30-patient pilot study, as well as the later U.S. pivotal study for spine fusion.
“This DBM supply agreement is an important milestone that allows us to advance rhNELL-1 for the $3 billion spine fusion market, with the goal of developing a product with compelling features and benefits versus existing commercial products,” Jeff Frelick, CEO of Bone Biologics told the press. “As we prepare to commence human clinical studies, we are delighted to partner with MTF Biologics, a highly-regarded industry innovator whose bone matrix will now comprise half of our combination product.”
Bone Biologics’ bone graft substitute rhNELL-1 for spinal fusion is in development and will be supplied by MTF for bone formation initiation and improvement. The agreement provides material for the company’s planned 30-patient pilot study, as well as the later U.S. pivotal study for spine fusion.
“This DBM supply agreement is an important milestone that allows us to advance rhNELL-1 for the $3 billion spine fusion market, with the goal of developing a product with compelling features and benefits versus existing commercial products,” Jeff Frelick, CEO of Bone Biologics told the press. “As we prepare to commence human clinical studies, we are delighted to partner with MTF Biologics, a highly-regarded industry innovator whose bone matrix will now comprise half of our combination product.”